Why carry out this study?

Erenumab-aooe was approved in the USA on 17 May 2018 for the preventive treatment of migraine in adults.

As a first-in-class option for migraine prevention, knowledge about the real-world experience of patients receiving erenumab is limited.

This study sought to examine the impact of erenumab treatment on migraine characteristics, comorbidities, healthcare resource utilization, and associated costs.

What was learned from the study?

Reductions in claims for important migraine characteristics, comorbidities, and a shift to decreased use of acute and preventive migraine medications in the post-erenumab follow-up period are indicative of the real-world effectiveness of erenumab.

Persistence to erenumab is an important factor requiring further examination.